Table 2 Bisphosphonates: potency, administration and main indications
Type of BPs | Potency | Administration | Main Indications |
|---|---|---|---|
NNBPs | |||
Etidronate | 1 | Oral | Osteoporosis, Paget’s disease of bone |
Clodronate | 10 | Oral/ Intravenous | Osteoporosis, Paget’s disease of bone |
Tiludronate | 10 | Oral | Paget’s disease of bone |
NBPs | |||
Pamidronate | 100 | Intravenous | Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, Paget’s disease of bone |
Alendonate | 500 | Oral | Osteoporosis, Paget's disease of bone |
Ibandronate | 1000 | Oral, Intravenous | Osteoporosis |
Risedronate | 2000 | Oral, Intravenous | Osteoporosis, Paget’s disease of bone, osteolytic lesions of multiple myeloma, hypercalcemia of malignancy |
Zoledronate | 10000 | Intravenous | Osteolytic lesions of multiple myeloma and metastases from solid tumors, hypercalcemia of malignancy |